Spero Therapeutics (SPRO) Stock: Buy, Sell, or Hold?
SPRO - Spero Therapeutics, Inc. Common Stock
$1.21
-0.01 (-0.82%)
âŧ
5d:
+0.83%
30d:
-4.72%
90d:
-57.09%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When SPRO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SPRO is fairly priced but lacks strong directional signals. At -35.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SPRO is fairly priced but lacks strong directional signals. At -35.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$6.29
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.91
69.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SPRO is currently trading at $1.21, which is considered fair relative to its 30-day fair value range of $1.19 to $1.24. From a valuation perspective, the stock is trading at a discount (Forward PE: 1.8) compared to its historical average (6.7). Remarkably, the market is currently pricing in an annual earnings decline of 35.4% over the next few years. This pessimistic expectation contrasts with the company's recent 75.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SPRO is in a strong downtrend. The price is currently testing key support at $1.18. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $4.00 (+230.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SPRO is in a strong downtrend. The price is currently testing key support at $1.18. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $4.00 (+230.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.19 -
$1.24
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (57/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 230.6% below Wall St target ($4.00)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.19 -
$1.24
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.18
Resistance Level
$1.26
Current Trend
Strong Downtrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.81
Wall Street Target
$4.00
(+230.6%)
Revenue Growth (YoY)
-95.6%
Earnings Growth (YoY)
75.3%
Profit Margin
15.7%
Valuation Discount vs History
-35.4% cheaper
PE vs Historical
1.8 vs 6.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-35.4%
(market-implied from PE analysis)
1-Year Target
$1.09
(-10%)
2-Year Target
$0.98
(-19%)
3-Year Target
$0.88
(-27%)
3-Yr Target (if PE normalizes)
(PE: 2â7)
$3.27
(+171%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (9x PE), but valuation improves significantly next year (2x PE) as earnings recover.
Trailing PE: 8.71 | Current EPS (TTM): $0.14
Bull Case
$2.68
(+122%)
Analyst growth 100.0%, PE expands to 9.6
Base Case
$2.44
(+102%)
Market implied 100.0%, PE stable at 8.7
Bear Case
$0.83
(-31%)
Severe decline -20.0%, PE contracts to 7.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.8 to 6.7
Stabilization Target:
$4.49
(+271.0%)
PE Expansion Potential:
+271.0%
Share & Embed Analysis
Last updated: September 07, 2026 3:40 AM ET
Data refreshes hourly during market hours. Next update: 4:40 AM
Data refreshes hourly during market hours. Next update: 4:40 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 52 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 45 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics IâĻ |
STRONG BUY
14 analysts |
$105 | 61 BUY |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
